EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET FORECAST 2021-2028

The Europe irritable bowel syndrome treatment market is estimated to project a CAGR of 7.16% during the forecast period, 2021-2028. The growing prevalence of gastrointestinal diseases like diarrhea and constipation, changing lifestyles, and the presence of key players, are driving market growth in the region.

To learn more about this report, request a free sample copy

The Europe irritable bowel syndrome treatment market growth evaluation includes the analysis of France, the United Kingdom, Belgium, Germany, Russia, Poland, Italy, and Rest of Europe. The UK has one of the largest healthcare systems, the National Health System, in Europe. It aims to create a patient-centric, responsive, and enhanced system, which is set to be beneficial for market growth. According to a review, two in ten people have IBS. The increasing geriatric population contributes to market growth. According to the Centre for Ageing Better report 2019, the population aged 65 and above was more than 11.9 million. The aging population is highly vulnerable to diseases like irritable bowel syndrome. Moreover, chronic diseases are becoming a considerable healthcare burden in the UK. Such factors are assessed to facilitate market growth in the UK. In Italy, IBS (Irritable Bowel Syndrome) is a common functional gastrointestinal disorder in primary and secondary care. According to a 2019 study, IBS with constipation was found in 43.4% of the total population. Also, the aging population is set to reach 27.9% by 2030, as per the World Population Ageing 2019 report. Thus, the rising prevalence of IBS is set to propel market growth in Italy.

Novartis AG has a strong presence in diverse biopharmaceutical segments. It is engaged in the manufacture, marketing, research, and development of medicines and generic pharmaceuticals. The company has its headquarters in Basel, Switzerland.

TABLE OF CONTENTS
  1. RESEARCH SCOPE & METHODOLOGY
    1. STUDY OBJECTIVES
    2. SCOPE OF STUDY
    3. METHODOLOGY
    4. ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    1. MARKET SIZE & ESTIMATES
    2. MARKET OVERVIEW
  3. MARKET DYNAMICS
    1. KEY DRIVERS
      1. RISE IN THE INCIDENCE OF GASTROINTESTINAL AILMENTS
      2. GROWING NUMBER OF DRUG DEVELOPMENTS AND FDA APPROVALS
      3. SURGING OCCURENCE OF IRRITABLE BOWEL SYNDROME
      4. INCREASING GERIATRIC POPULATION
    2. KEY RESTRAINTS
      1. HIGH COST OF DRUGS
      2. LIMITED TREATMENT OPTIONS
  4. KEY ANALYTICS
    1. PORTER’S FIVE FORCES ANALYSIS
      1. THREAT OF NEW ENTRY
      2. THREAT OF SUBSTITUTION
      3. BUYER’S POWER
      4. SUPPLIER’S POWER
      5. COMPETITIVE RIVALRY
    2. IMPACT OF COVID-19 ON IRRITABLE BOWEL SYNDROME TREATMENT MARKET
    3. OPPORTUNITY MATRIX
    4. VENDOR LANDSCAPE
    5. KEY INVESTMENT INSIGHTS
  5. MARKET BY TYPE
    1. IBS WITH DIARRHEA
    2. IBS WITH CONSTIPATION
    3. MIXED IBS
  6. MARKET BY PRODUCT
    1. RIFAXIMIN
    2. ELUXADOLINE
    3. LINACLOTIDE
    4. LUBIPROSTONE
    5. OTHER PRODUCTS
  7. MARKET BY DISTRIBUTION CHANNEL
    1. DRUG STORES AND RETAIL PHARMACIES
    2. HOSPITALS’ PHARMACIES
    3. ONLINE PHARMACIES
  8. MARKET BY MECHANISM OF ACTION
    1. 5HT3 ANTAGONIST
    2. GUANYLATE CYCLASE RECEPTOR-C AGONIST
    3. CHLORIDE CHANNEL ACTIVATOR
    4. OTHER MECHANISM OF ACTIONS
  9. MARKET BY DOSAGE
    1. SOLID
    2. LIQUID
  10. GEOGRAPHICAL ANALYSIS
    1. EUROPE
      1. MARKET SIZE & ESTIMATES
      2. KEY GROWTH ENABLERS
      3. KEY CHALLENGES
      4. KEY PLAYERS
      5. COUNTRY ANALYSIS
        1. GERMANY
        2. FRANCE
        3. UNITED KINGDOM
        4. ITALY
        5. RUSSIA
        6. BELGIUM
        7. POLAND
        8. REST OF EUROPE
  11. COMPETITIVE LANDSCAPE
    1. KEY STRATEGIC DEVELOPMENTS
      1. MERGER & ACQUISITIONS
      2. PRODUCT LAUNCH & DEVELOPMENTS
      3. PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
      4. BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
    2. COMPANY PROFILE
      1. ABBOTT LABORATORIES
      2. BAUSCH HEALTH COMPANIES INC
      3. ALLERGAN PLC
      4. ARDELYX INC
      5. ASTELLAS PHARMA INC
      6. ASTRAZENECA PLC
      7. GLAXOSMITHKLINE PLC
      8. IRONWOOD PHARMACEUTICALS INC
      9. JOHNSON & JOHNSON (MCNEIL CONSUMER HEALTHCARE)
      10. LANNETT COMPANY INC
      11. NOVARTIS AG
      12. SEBELA PHARMACEUTICALS INC
      13. SYNTHETIC BIOLOGICS INC
      14. TAKEDA PHARMACEUTICAL COMPANY LTD
LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - IRRITABLE BOWEL SYNDROME TREATMENT

TABLE 2: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 3: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 4: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 5: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 6: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 7: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 8: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 9: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 10: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 11: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 12: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)

TABLE 13: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)

TABLE 14: LEADING PLAYERS OPERATING IN EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET

LIST OF FIGURES

FIGURE 1: PORTER’S FIVE FORCE ANALYSIS

FIGURE 2: OPPORTUNITY MATRIX

FIGURE 3: VENDOR LANDSCAPE

FIGURE 4: KEY INVESTMENT INSIGHTS

FIGURE 5: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY TYPE, IN 2020

FIGURE 6: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH DIARRHEA, 2021-2028 (IN $ MILLION)

FIGURE 7: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY IBS WITH CONSTIPATION, 2021-2028 (IN $ MILLION)

FIGURE 8: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MIXED IBS, 2021-2028 (IN $ MILLION)

FIGURE 9: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY PRODUCT, IN 2020

FIGURE 10: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY RIFAXIMIN, 2021-2028 (IN $ MILLION)

FIGURE 11: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ELUXADOLINE, 2021-2028 (IN $ MILLION)

FIGURE 12: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LINACLOTIDE, 2021-2028 (IN $ MILLION)

FIGURE 13: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LUBIPROSTONE, 2021-2028 (IN $ MILLION)

FIGURE 14: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER PRODUCTS, 2021-2028 (IN $ MILLION)

FIGURE 15: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DISTRIBUTION CHANNEL, IN 2020

FIGURE 16: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DRUG STORES AND RETAIL PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 17: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY HOSPITALS’ PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 18: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY ONLINE PHARMACIES, 2021-2028 (IN $ MILLION)

FIGURE 19: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY MECHANISM OF ACTION, IN 2020

FIGURE 20: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY 5HT3 ANTAGONIST, 2021-2028 (IN $ MILLION)

FIGURE 21: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY GUANYLATE CYCLASE RECEPTOR-C AGONIST, 2021-2028 (IN $ MILLION)

FIGURE 22: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY CHLORIDE CHANNEL ACTIVATOR, 2021-2028 (IN $ MILLION)

FIGURE 23: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY OTHER MECHANISM OF ACTIONS, 2021-2028 (IN $ MILLION)

FIGURE 24: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY DOSAGE, IN 2020

FIGURE 25: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY SOLID, 2021-2028 (IN $ MILLION)

FIGURE 26: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, BY LIQUID, 2021-2028 (IN $ MILLION)

FIGURE 27: EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)

FIGURE 28: GERMANY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 29: FRANCE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 30: UNITED KINGDOM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 31: ITALY IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 32: RUSSIA IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 33: BELGIUM IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 34: POLAND IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

FIGURE 35: REST OF EUROPE IRRITABLE BOWEL SYNDROME TREATMENT MARKET, 2021-2028 (IN $ MILLION)

Request For A Free Sample